Evidence-Based Medicine in the EMR Era

Students working with an artificial patient (F...Image via Wikipedia

Evidence-Based Medicine in the EMR Era

Jennifer Frankovich, M.D., Christopher A. Longhurst, M.D., and Scott M. Sutherland, M.D.
November 2, 2011 (10.1056/NEJMp1108726)

Many physicians take great pride in the practice of evidence-based medicine. Modern medical education emphasizes the value of the randomized, controlled trial, and we learn early on not to rely on anecdotal evidence. But the application of such superior evidence, however admirable the ambition, can be constrained by trials’ strict inclusion and exclusion criteria — or the complete absence of a relevant trial. For those of us practicing pediatric medicine, this reality is all too familiar. In such situations, we are used to relying on evidence at Levels III through V — expert opinion — or resorting to anecdotal evidence. What should we do, though, when there aren’t even meager data available and we don’t have a single anecdote on which to draw?
We recently found ourselves in such a situation as we admitted to our service a 13-year-old girl with systemic lupus erythematosus (SLE). Our patient‘s presentation was complicated by nephrotic-range proteinuria, antiphospholipid antibodies, and pancreatitis. Although anticoagulation is not standard practice for children with SLE even when they’re critically ill, these additional factors put our patient at potential risk for thrombosis, and we considered anticoagulation. However, we were unable to find studies pertaining to anticoagulation in our patient’s situation and were therefore reluctant to pursue that course, given the risk of bleeding. A survey of our pediatric rheumatology colleagues — a review of our collective Level V evidence, so to speak — was equally fruitless and failed to produce a consensus.
Without clear evidence to guide us and needing to make a decision swiftly, we turned to a new approach, using the data captured in our institution’s electronic medical record (EMR) and an innovative research data warehouse. The platform, called the Stanford Translational Research Integrated Database Environment (STRIDE), acquires and stores all patient data contained in the EMR at our hospital and provides immediate advanced text searching capability.1 Through STRIDE, we could rapidly review data on an SLE cohort that included pediatric patients with SLE cared for by clinicians in our division between October 2004 and July 2009. This “electronic cohort” was originally created for use in studying complications associated with pediatric SLE and exists under a protocol approved by our institutional review board.
Of the 98 patients in our pediatric lupus cohort, 10 patients developed thrombosis, documented in the EMR, while they were acutely ill. The prevalence was higher among patients who had persistent nephrotic-range proteinuria and pancreatitis (see tableResults of Electronic Search of Patient Medical Records (for a Cohort of 98 Pediatric Patients with Lupus) Focused on Risk Factors for Thrombosis Relevant to Our 13-Year-Old Patient with Systemic Lupus Erythematosus.). As compared with our patients with lupus who did not have these risk factors, the risk of thrombosis was 14.7 (95% confidence interval [CI], 3.3 to 96) among patients with persistent nephrosis and 11.8 (95% CI, 3.8 to 27) among those with pancreatitis. This automated cohort review was conducted in less than 4 hours by a single clinician. On the basis of this real-time, informatics-enabled data analysis, we made the decision to give our patient anticoagulants within 24 hours after admission.
Our case is but one example of a situation in which the existing literature is insufficient to guide the clinical care of a patient. But it illustrates a novel process that is likely to become much more standard with the widespread adoption of EMRs and more sophisticated informatics tools. Although many other groups have highlighted the secondary use of EMR data for clinical research,2,3 we have now seen how the same approach can be used to guide real-time clinical decisions. The rapid electronic chart review and analysis were not only feasible, but also more helpful and accurate than physician recollection and pooled colleague opinion. Such real-time availability of data to guide decision making has already transformed other industries,4 and the growing prevalence of EMRs along with the development of sophisticated tools for real-time analysis of deidentified data sets will no doubt advance the use of this data-driven approach to health care delivery. We look forward to a future in which health information systems help physicians learn from every patient at every visit and close the feedback loop for clinical decision making in real time.
Did we make the correct decision for our patient? Thrombosis did not develop, and the patient did not have any sequelae related to her anticoagulation; truthfully, though, we may never really know. We will, however, know that we made the decision on the basis of the best data available — acting, as the fictional detective Nero Wolfe would say, “in the light of experience as guided by intelligence.”5 In the practice of medicine, one can’t do better than that.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
This article (10.1056/NEJMp1108726) was published on November 2, 2011, at NEJM.org.


From the Division of Rheumatology (J.F.), the Division of Systems Medicine (C.A.L.), and the Division of Nephrology (S.M.S.), Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA.


  1. 1
    Lowe HJ, Ferris TA, Hernandez PM, Weber SC. STRIDE — an integrated standards-based translational research informatics platform. AMIA Annu Symp Proc 2009;14:391-395
  2. 2
    Prokosch HU, Ganslandt T. Perspectives for medical informatics: reusing the electronic medical record for clinical research. Methods Inf Med 2009;48:38-44
    Web of Science | Medline
  3. 3
    Gunn PW, Hansen ML, Kaelber DC. Underdiagnosis of pediatric hypertension — an example of a new era of clinical research enabled by electronic medical records. AMIA Annu Symp Proc 2007;11:966-966
  4. 4
    Halevy A, Norvig P, Pereira F. The Unreasonable Effectiveness of Data. IEEE Intelligent Systems, March/April 2009:8-12.
  5. 5
    Stout R. In the best families. New York: Viking Press, 1950:71.

Pediatric deaths due to varicella are becoming a thing of the past

Varicella simplex (Chickenpox) on a child Skull.                       Image via Wikipedia Source: MD Consult

ST LOUIS (MD Consult) – With implementation of the varicella vaccination program in the United States, deaths due to the disease among children and adolescents have virtually ceased, finds a study reported in the August 2011 issue of Pediatrics.

Using data from the Mortality Multiple Cause-of-Death records of the US National Center for Health Statistics, investigators analyzed temporal patterns of deaths among individuals of all ages for which varicella was listed as an underlying or contributing cause between 1990 and 2007. The vaccination program was introduced in 1995.

Over the first 12 years of the program, the annual average mortality rate for varicella listed as the underlying cause fell by 88%, from 0.41 per million population in 1990-1994 to 0.05 per million population in 2005-2007.

The same pattern was evident across all age-groups. The reduction was 97%, 90%, and 67% among children and adolescents younger than 20 years, among adults aged 20 to 49 years, and among adults aged 50 years or older, respectively.

In the last 6 years analyzed (2002-2007), there were 3 deaths each among children aged 1 to 4 years and aged 5 to 9 years; in sharp contrast, there were an average of 13 and 16 deaths annually, respectively, before the vaccine was introduced.

All of the deaths among children and adolescents younger than 20 years in 2002-2007 occurred in those who did not have high-risk conditions as strictly defined by the study, although 3 occurred in children or adolescents having conditions that could increase risk.

“The impressive decline in varicella deaths can be directly attributed to successful implementation of the 1-dose vaccination program,” the investigators conclude. “With the current 2-dose program, there is potential that these most severe outcomes of a vaccine-preventable disease could be eliminated.”

Pediatrics. 2011;128:214-220.

Enhanced by Zemanta